Profound Medical
NASDAQ: PROF2 known investors
Profound Medical develops the MRI-guided TULSA Procedure (TULSA-PRO), an incision-free transurethral ultrasound ablation system for treating prostate tissue in men with conditions such as localized prostate cancer. The device uses real-time MRI temperature monitoring and closed-loop feedback to ablate targeted prostate tissue while aiming to preserve erectile function and urinary continence.
HealthtechMedical Devices
Investors · 2
Frequently asked questions
- What does Profound Medical do?
- Profound Medical develops the MRI-guided TULSA Procedure (TULSA-PRO), an incision-free transurethral ultrasound ablation system for treating prostate tissue in men with conditions such as localized prostate cancer. The device uses real-time MRI temperature monitoring and closed-loop feedback to ablate targeted prostate tissue while aiming to preserve erectile function and urinary continence.
- Who are Profound Medical's investors?
- Profound Medical's investors include CTI Life Sciences Fund L.P., FACIT (Fight Against Cancer Innovation Trust).